Physician profile
Gregory B Dye
NPI 1275528937
$737.27
in general payments reported to CMS, 2019-2025
16 companies · $35.94 in 2025
The $35.94 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $50.54 · 2021: $227 · 2022: $111 · 2023: $109 · 2024: $63.26 · 2025: $35.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $208.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $215.32 | 2020-2025 | Vraylar |
| Novo Nordisk INC | $102.81 | 2019-2025 | Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $62.51 | 2019-2022 | |
| Lilly USA, LLC | $58.94 | 2021-2023 | Mounjaro |
| Amgen INC. | $48.91 | 2019 | |
| Abbott Laboratories | $47.11 | 2021-2022 | |
| Insulet Corporation | $35.07 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $31.56 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $27.84 | 2023 | Rexulti |
| Hologic Sales and Service, LLC | $19.36 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.48 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.49 | 2021 | |
| Xeris Pharmaceuticals, INC. | $15.43 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.62 | 2020 | |
| Daiichi Sankyo INC. | $13.47 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $11.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Dye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.